Schonfeld Strategic Advisors LLC Purchases New Shares in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Schonfeld Strategic Advisors LLC purchased a new position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 101,881 shares of the company's stock, valued at approximately $1,000,000. Schonfeld Strategic Advisors LLC owned approximately 0.18% of Ginkgo Bioworks as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Northern Trust Corp boosted its stake in shares of Ginkgo Bioworks by 11.5% in the fourth quarter. Northern Trust Corp now owns 94,876 shares of the company's stock worth $932,000 after acquiring an additional 9,791 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in Ginkgo Bioworks in the 4th quarter worth approximately $1,796,000. Price T Rowe Associates Inc. MD grew its holdings in Ginkgo Bioworks by 4.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 82,815 shares of the company's stock valued at $814,000 after buying an additional 3,152 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Ginkgo Bioworks during the fourth quarter valued at approximately $665,000. Finally, Jump Financial LLC purchased a new position in shares of Ginkgo Bioworks in the fourth quarter worth $505,000. 78.63% of the stock is owned by institutional investors.

Ginkgo Bioworks Trading Down 3.6%

Shares of NYSE:DNA traded down $0.30 during midday trading on Tuesday, reaching $8.01. 425,267 shares of the company were exchanged, compared to its average volume of 1,468,182. The stock has a market cap of $464.85 million, a PE ratio of -0.61 and a beta of 1.29. The business's fifty day moving average is $7.13 and its two-hundred day moving average is $9.08. Ginkgo Bioworks Holdings, Inc. has a one year low of $5.00 and a one year high of $38.58.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. The company had revenue of $48.32 million for the quarter, compared to the consensus estimate of $38.70 million. As a group, sell-side analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current year.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.